ArticleCommunications medicine2026
High-dimensional profiling following third MMR vaccination or mumps virus infection reveals individuals with suboptimal immunity.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterindividual variation in vaccine responsiveness can help to identify tailored vaccine strategies for groups with suboptimal responses and potentially higher risk.
methodsHere we assessed and compared such interindividual variation in humoral and cellular immune responses following a third Mumps-Measles-Rubella (MMR3) immunization and mumps virus infection in young adults with a multiparameter analysis.
resultsWe demonstrate that MMR3 boosts (neutralizing) antibody, IgG
conclusionsOverall, our results indicate that a third MMR immunization boosts humoral and cellular responses in young adults albeit with clear distinct immune response profiles. This may enable the identification and more effective targeting of groups with suboptimal immunity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.